Matrix metalloproteinase-2, Matrix metalloproteinase-9, Matrix metalloproteinase-13 (MMP-2, MMP-9, MMP-13)

Matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), and matrix metalloproteinase-13 (MMP-13) are zinc-dependent endopeptidases that degrade components of the extracellular matrix such as collagens, gelatins, and fibronectin[1][2][7]. They play central roles in tissue remodeling, wound healing, inflammation, and pathological conditions such as cancer, fibrosis, and cardiovascular diseases. MMP-2 and MMP-9 are also known as type IV collagenases (gelatinases), while MMP-13 is primarily a collagenase specialized in degrading collagens in bone and cartilage. Dysregulation of these MMPs leads to pathological destruction or remodeling of extracellular matrix and is implicated in the initiation and progression of various diseases, making them important therapeutic targets. However, therapeutic targeting is complicated by their broad biological roles and challenges with inhibitor selectivity[1][4][7][8].

Other names

Gelatinase A72 kDa type IV collagenaseGelatinase B92 kDa type IV collagenaseCollagenase 3

Inhibition of proteolytic activity (prevents ECM degradation) Anti-tumor invasion and anti-metastatic mechanisms Anti-fibrotic effects (by blocking extracellular matrix remodeling) Modulation of immune response (reducing inflammatory cell migration) Inhibition of angiogenesis (affecting new blood vessel formation)